Preclinical Comparison of the Amyloid-β Radioligands [11C]Pittsburgh compound B and [18F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis

[1]  Stefan Wiehr,et al.  Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion , 2014, Nature Medicine.

[2]  Jochen Herms,et al.  Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [18F]-florbetaben PET , 2014, NeuroImage.

[3]  Habib Zaidi,et al.  Amyloid-β positron emission tomography imaging probes: a critical review. , 2013, Journal of Alzheimer's disease : JAD.

[4]  M. Scheinin,et al.  Longitudinal Amyloid Imaging in Mouse Brain with 11C-PIB: Comparison of APP23, Tg2576, and APPswe-PS1dE9 Mouse Models of Alzheimer Disease , 2013, The Journal of Nuclear Medicine.

[5]  D. Pareto,et al.  In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography , 2013, Neurobiology of Aging.

[6]  P. Cumming,et al.  Longitudinal Assessment of Cerebral β-Amyloid Deposition in Mice Overexpressing Swedish Mutant β-Amyloid Precursor Protein Using 18F-Florbetaben PET , 2013, The Journal of Nuclear Medicine.

[7]  Agneta Nordberg,et al.  Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. , 2013, Brain : a journal of neurology.

[8]  Colin L. Masters,et al.  Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia , 2013, The Journal of Nuclear Medicine.

[9]  M. Czisch,et al.  Voxel-Based Analysis of Amyloid-Burden Measured with [11C]PiB PET in a Double Transgenic Mouse Model of Alzheimer’s Disease , 2013, Molecular Imaging and Biology.

[10]  M. Mintun,et al.  Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.

[11]  James Robert Brašić,et al.  An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients , 2013, Molecular Imaging and Biology.

[12]  L. Barré,et al.  PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition , 2012, Neurobiology of Aging.

[13]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[14]  M. Scheinin,et al.  Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  William J. Jagust,et al.  Brain imaging in the study of Alzheimer's disease , 2012, NeuroImage.

[16]  Mark A. van Buchem,et al.  Monitoring blood flow alterations in the Tg2576 mouse model of Alzheimer's disease by in vivo magnetic resonance angiography at 17.6T , 2012, NeuroImage.

[17]  Stefan Platzer,et al.  Small-Animal PET Imaging of Amyloid-Beta Plaques with [11C]PiB and Its Multi-Modal Validation in an APP/PS1 Mouse Model of Alzheimer's Disease , 2012, PloS one.

[18]  C. Rowe,et al.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Christer Halldin,et al.  Clinical Validation of 18F-AZD4694, an Amyloid-β–Specific PET Radioligand , 2012, The Journal of Nuclear Medicine.

[20]  A. Nordberg.  Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development , 2011, Alzheimer's Research & Therapy.

[21]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[22]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[23]  Vladimir Kepe,et al.  Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates , 2010, Proceedings of the National Academy of Sciences.

[24]  O. Sabri,et al.  Metabolite analysis of [18F]Florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial , 2010 .

[25]  Victor W Pike,et al.  PET radiotracers: crossing the blood-brain barrier and surviving metabolism. , 2009, Trends in pharmacological sciences.

[26]  L. Thurfjell,et al.  Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.

[27]  C. Rowe,et al.  Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias , 2009, Journal of Nuclear Medicine.

[28]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[29]  Joanna S. Fowler,et al.  A novel approach for imaging brain–behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator , 2007, NeuroImage.

[30]  Tetsuya Suhara,et al.  Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.

[31]  V. Libri,et al.  PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. , 2007, Brain : a journal of neurology.

[32]  Bin Yuan,et al.  Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models , 2006 .

[33]  Hartwig Wolburg,et al.  Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology , 2006, EMBO reports.

[34]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[35]  S. DeKosky,et al.  Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.

[36]  J. Hardy,et al.  Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice , 2005, Neuron.

[37]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  Michael V. Green,et al.  PET imaging of brain with the β-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[40]  C. C. Watson,et al.  New, faster, image-based scatter correction for 3D PET , 1999, 1999 IEEE Nuclear Science Symposium. Conference Record. 1999 Nuclear Science Symposium and Medical Imaging Conference (Cat. No.99CH37019).

[41]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[42]  Michel Defrise,et al.  Exact and approximate rebinning algorithms for 3-D PET data , 1997, IEEE Transactions on Medical Imaging.

[43]  H. Malcolm Hudson,et al.  Accelerated image reconstruction using ordered subsets of projection data , 1994, IEEE Trans. Medical Imaging.

[44]  D. Selkoe.  The molecular pathology of Alzheimer's disease , 1991, Neuron.